ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 29

A Novel CD27(-) B-Cell Subset Identified Based On Intracellular Characteristics Is Expanded In SLE

S.J. Fleischer1, Capucine Daridon2 and Thomas Dörner3, 1Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, 2Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, 3CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, SLE and syk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cell Function and Targeting in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Several studies linked the emergence of autoimmunity to abnormalities of the B-cell receptor (BCR) due to disturbances of signaling molecules or its co-receptors. Therefore this study focused on spleen tyrosine kinase (Syk), a key molecule of early BCR signaling in autoimmunity. Our model is systemic lupus erythematosus (SLE) which is an autoimmune disease known to be associated with a breakdown of self-tolerance resulting in auto-antibody production, B-cell hyper-reactivity and disturbed B-cell homeostasis of peripheral B-cell subsets.

Methods: Peripheral blood was taken from 31 healthy, 61 SLE patients, 15 patients with rheumatoid arthritis (RA) and 16 primary Sjögren’s syndrome (pSS) patients. The expression of Syk and basal / BCR-induced phosphorylation of Syk by B-cells were studied by phosphoflow analysis. To assess the localization of Syk within B-cells, immunofluorescence was performed and analyzed by confocal microscopy. In addition, characterization of B-cells was evaluated by flow cytometry using the following markers CD19, CD20, CD27, CD38, IgD, CD95 and Ki67. Finally, the capacity of B-cells to differentiate into antibody producing cells was evaluated by flow cytometry and Elispot after 5 days of in vitro culture.

Results: In this study, two different subsets according their expression of Syk (Sykbright and Sykdim) within the CD20+CD27(-) population have been identified. The frequency of CD27(-)Sykbright B-cells were significantly increased in SLE compare to HD, however the disease activity (SLEDAI) do not correlate with the frequency of this subset. No significant increase in the frequency of this population was observed in others autoimmune diseases (i.e. RA and pSS). This subset showed an accumulation of Syk within the cytoplasm, a superior response to the BCR and plasma cell differentiation compared to CD27(-) Sykdim B-cells. Finally, this subset exhibited a memory-like phenotype.

Conclusion: A novel subset of B-cells defined as CD27(-)Sykbright B-cells and carrying memory features has been identified in SLE patients. This population represents a prime candidate how peripheral check point control of conventional B cells can be possibly bypassed in SLE.


Disclosure:

S. J. Fleischer,
None;

C. Daridon,
None;

T. Dörner,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-cd27-b-cell-subset-identified-based-on-intracellular-characteristics-is-expanded-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology